DEA fee waiver
This article was originally published in The Tan Sheet
Executive Summary
Denying a registration waiver to distributors who handle controlled substances as well as List I chemicals would disproportionately raise fees by requiring them to file separate registrations, four trade organizations state in Jan. 17 comments to the Drug Enforcement Administration. The Consumer Healthcare Products Association, the Food Marketing Institute, the Healthcare Distribution Management Association and the National Association of Chain Drug Stores submitted joint comments addressing the possible removal of the List I registration waiver. "A single controlled substances distributor that is also a List I chemical handler would see a fee increase from $813 to $2,386 - nearly a three-fold increase - under this redundant fee scenario," they state. Maintaining two DEA registration numbers would also create "significant paperwork and operational burdens" for the agency and the industry. The DEA should retain the waiver for List I and controlled substances distributors, and provide information on the anticipated results of such fees, the organizations state...
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.